Show simple item record

dc.contributor.authorSosa, Nestor
dc.contributor.authorCapitan, Zeus
dc.contributor.authorNieto, Javier
dc.contributor.authorNieto, Melissa
dc.contributor.authorCalzada, Jose
dc.contributor.authorPaz, Hector
dc.contributor.authorSpadafora, Carmenza
dc.contributor.authorKreishman, Mara Deitric
dc.contributor.authorKopydlowski, Karen
dc.contributor.authorUllman, Diane
dc.contributor.authorMcCarthy, William F.
dc.contributor.authorRansom, Janet
dc.contributor.authorBerman, Jonathan
dc.contributor.authorScott, Charles
dc.contributor.authorGrogl, Max
dc.date.accessioned2020-06-04T23:11:37Z
dc.date.available2020-06-04T23:11:37Z
dc.date.issued2013-07-15
dc.identifier.otherdoi:10.4269/ajtmh.12-0736
dc.identifier.urihttp://repositorio-indicasat.org.pa/handle/123456789/45
dc.descriptionIn this randomized, double-blinded Phase 2 trial, 30 patients with Leishmania panamensis cutaneous leishmaniasis were randomly allocated (1:1) to receive once daily topical treatment with WR 279,396 (15% paromomycin + 0.5% gentamicin) or Paromomycin Alone (15% paromomycin) for 20 days. The index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone (P = 0.099). When all treated lesions were included, the final cure rate for WR 279,398-treated patients was again 87%, but the final cure rate for Paromomycin Alone-treated patients was 8 of 15 (53.3%; P = 0.046). Both creams were well tolerated with mild application site reactions being the most frequent adverse event. The increased final cure rate in the WR 279,396 group in this small Phase 2 study suggests that the combination product may provide greater clinical benefit than paromomycin monotherapy against L. panamensis cutaneous leishmaniasis.en_US
dc.description.abstractIn this randomized, double-blinded Phase 2 trial, 30 patients with Leishmania panamensis cutaneous leishmaniasis were randomly allocated (1:1) to receive once daily topical treatment with WR 279,396 (15% paromomycin + 0.5% gentamicin) or Paromomycin Alone (15% paromomycin) for 20 days. The index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone (P = 0.099). When all treated lesions were included, the final cure rate for WR 279,398-treated patients was again 87%, but the final cure rate for Paromomycin Alone-treated patients was 8 of 15 (53.3%; P = 0.046). Both creams were well tolerated with mild application site reactions being the most frequent adverse event. The increased final cure rate in the WR 279,396 group in this small Phase 2 study suggests that the combination product may provide greater clinical benefit than paromomycin monotherapy against L. panamensis cutaneous leishmaniasis.en_US
dc.language.isoenen_US
dc.subjectRandomizeden_US
dc.subjectDouble-Blindeden_US
dc.subjectParomomycin and Gentamicinen_US
dc.titleRandomized, Double-Blinded, Phase 2 Trial of WR 279,396 (Paromomycin and Gentamicin) for Cutaneous Leishmaniasis in Panamaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record